Developer docs
API playgroundTry for free, no card

Search company profiles

iFyber

Full company profile

uuid0009jak

Namestring
iFyber
Legal namestring
iFyber, LLC
Websiteurl
ifyber.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

iFyber, LLC is a preclinical contract research organization (CRO) founded in 2009 and based in Ithaca, New York, providing fee-for-service laboratory testing and regulatory consulting to companies developing medical devices, wound care products, diagnostics, and specialty textiles. The company's service catalog is organized around four technical pillars: microbial control (biofilm testing, antimicrobial efficacy testing, and sterilization validation); cell and tissue culture (cell-based assays, ex vivo porcine dermal models, 3D Human Epidermis Equivalent tissue models, and histology/imaging); LC-MS analytical services for proteomics, biomarker, and small-molecule analysis; and virology plus analytical chemistry including monoclonal antibody characterization and chemical detection diagnostics. Notable proprietary methodology includes the ex vivo porcine dermal biofilm model—documented in multiple white papers—that bridges in vitro screening and in vivo animal studies for antimicrobial and anti-biofilm work, and the 3D HEE tissue model for wound care and biomaterials testing.

iFyber operates as a B2B enterprise services business, engaging clients through direct sales, website contact, and email to scope custom project work; pricing is not publicly disclosed and contracts are quoted on a per-project basis. Primary customer segments are medical device and wound care developers—often requiring FDA 510(k) submission support, biocompatibility evaluation, and antimicrobial or biofilm efficacy testing—supplemented by diagnostics companies and specialty textile manufacturers. The company has produced at least one disclosed co-development engagement, a 2021 collaboration with SweetBio, Inc. evaluating the APIS wound product via a joint publication in the International Journal of Biomaterials. No institutional venture capital is disclosed; the only recorded funding event is a $150,000 National Science Foundation grant in December 2012, suggesting the company has been bootstrapped or founder-financed for most of its operating life. Leadership team, headcount exact figure, and revenue figures are not disclosed in the public source set, indicating a small, privately held operation (headcount stated as 11–50 employees) operating primarily in North America.

Short descriptiontext

iFyber is a U.S.-based preclinical contract research organization (CRO) providing custom laboratory testing and regulatory consulting—including biofilm, antimicrobial, tissue model, LC-MS, and virology services—to medical device, wound care, diagnostic, and specialty textile developers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersIthaca, United States
HQ citystring
Ithaca
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical CRO, contract research, medical device testing, antimicrobial efficacy testing, biofilm testing services
Industry3 codes
PRIMARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYAFALADAC
Regulatory Consulting & Compliance Program Management (FDA/USDA/EFSA)
Agriculture & Food Production/Food Safety, Testing & Certification/Regulatory Compliance Testing & Consulting (FDA/USDA/EFSA, HACCP)
NAICS code3 codes
  • Testing Laboratories and Services541380
  • Other Scientific and Technical Consulting Services541690
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Preclinical Contract Research Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Fee-for-service preclinical research contracts providing laboratory testing, method development, and regulatory consulting to medical device, wound care, diagnostics, and specialty textile companies.

ifyber.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

iFyber is a preclinical contract research organization (CRO) that provides fee-for-service laboratory testing, custom method development, and regulatory consulting to medical device, wound care, diagnostics, and specialty textile companies. Its services span microbial control (biofilm testing, antimicrobial efficacy, sterilization validation), cell and tissue culture (cell-based assays, ex vivo and 3D tissue models, histology and imaging), LC-MS analytical chemistry, virology testing, monoclonal antibody characterization, and chemical detection diagnostics.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

iFyber is a preclinical contract research organization (CRO) providing integrated research services for medical device, wound care, diagnostic, and specialty textile development. The company operates as a unified service platform rather than a software product, offering consulting-driven experimental design combined with laboratory execution across multiple testing disciplines. The portfolio encompasses microbial control services (biofilm testing, antimicrobial efficacy testing, sterilization validation), cell and tissue culture capabilities (cell-based assays, tissue models including ex vivo porcine dermal models and 3D Human Epidermis Equivalent, histology and imaging), LC-MS analytical services, virology testing, analytical services for monoclonal antibodies and chemical detection, and specialized expertise in medical devices, wound care devices, diagnostics, and specialty textiles. White papers documenting proprietary methodologies include ex vivo biofilm models, biofilm visualization techniques, 3D HEE models, dental device biocompatibility frameworks, antibiotic and antifungal efficacy screening, and tissue decellularization evaluation.

Product and service2 records
1Preclinical CRO Services
CategoryContract Research Organization
Description

Integrated preclinical contract research services encompassing study design, experimental execution, and regulatory consulting to support medical device, wound care, diagnostic, and specialty textile product development.

2Microbial Control Services
Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-03-23
Description

Collaborative research partnership for wound care product evaluation. Joint publication titled 'Microenvironment Influence of a Novel Bioengineered Wound Product, APIS®: A Preliminary In Vitro Analysis of Inflammatory Marker and Growth Factor Secretion' published in International Journal of Biomaterials (2021). The partnership evaluated the novel APIS wound product's ability to balance wound microenvironment by reducing MMP-9/TIMP-1 ratio and triggering growth factor release from fibroblasts.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Nelson Labs is a dedicated microbiology and analytical testing CRO specializing in medical device sterilization validation, biocompatibility, and antimicrobial efficacy testing. It is a direct peer to iFyber given the highly overlapping focus on medical device and wound care product safety, efficacy, and FDA submission-support testing.

TypeDirect peer
Description

Toxikon is a preclinical CRO focused on medical device biocompatibility, toxicology, and materials characterization. It directly competes with iFyber's medical device safety and biocompatibility testing work for FDA submissions.

TypeBroad incumbent
Description

Labcorp's development services business spans central lab, preclinical, and analytical services across pharma and medtech. It is a broad incumbent whose central lab and preclinical offerings overlap with iFyber's analytical and preclinical testing capabilities.

TypeBroad incumbent
Description

Eurofins is a global analytical testing incumbent with dedicated medical device, pharmaceutical, and microbiology service lines. It is comparable as a broad incumbent offering overlapping antimicrobial, biocompatibility, and analytical services—though at much greater scale and geographic breadth than iFyber.

TypeBroad incumbent
Description

WuXi AppTec is a large global CRO/CDMO with preclinical testing, analytical chemistry, and regulatory capabilities. It is comparable as a broad incumbent offering testing services that overlap with iFyber's preclinical and analytical offerings, primarily serving medical device and biopharma clients.

TypeBroad incumbent
Description

Charles River is a global life sciences CRO incumbent with significant preclinical safety, microbiology, and endotoxin testing capabilities. It is comparable as a broad incumbent serving medical device and biopharma end-markets that also overlap with iFyber's preclinical testing focus.

TypeEmerging player
Description

Pace Analytical provides analytical and life sciences testing services including microbiology and chemistry for regulated industries. It is an emerging/larger-but-focused player whose analytical chemistry and microbiology capabilities partially overlap with iFyber's LC-MS and microbial control services.

8Microtest Laboratories
TypeDirect peer
Description

Microtest Laboratories is a contract testing lab focused on medical device microbiology, sterilization validation, and packaging/testing services. It is a direct peer to iFyber given the overlapping focus on medical device antimicrobial efficacy and sterilization validation workflows.

TypeBroad incumbent
Description

BioReliance is a biopharmaceutical testing services provider offering biosafety, analytical, and microbiology testing to medical product developers. It is comparable as a broad incumbent whose microbiology and analytical offerings overlap with iFyber's antimicrobial and LC-MS work.

10North American Science Associates (NAMSA)
TypeDirect peer
Description

NAMSA is a medical device-focused CRO offering preclinical, biological safety, and regulatory consulting services. It directly competes with iFyber's integrated preclinical testing plus FDA 510(k) regulatory support for medical device developers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iFyber

Preclinical Contract Research Servicesifyber.com

iFyber is a U.S.-based preclinical contract research organization (CRO) providing custom laboratory testing and regulatory consulting—including biofilm, antimicrobial, tissue model, LC-MS, and virology services—to medical device, wound care, diagnostic, and specialty textile developers.

What iFyber does

iFyber, LLC is a preclinical contract research organization (CRO) founded in 2009 and based in Ithaca, New York, providing fee-for-service laboratory testing and regulatory consulting to companies developing medical devices, wound care products, diagnostics, and specialty textiles. The company's service catalog is organized around four technical pillars: microbial control (biofilm testing, antimicrobial efficacy testing, and sterilization validation); cell and tissue culture (cell-based assays, ex vivo porcine dermal models, 3D Human Epidermis Equivalent tissue models, and histology/imaging); LC-MS analytical services for proteomics, biomarker, and small-molecule analysis; and virology plus analytical chemistry including monoclonal antibody characterization and chemical detection diagnostics. Notable proprietary methodology includes the ex vivo porcine dermal biofilm model—documented in multiple white papers—that bridges in vitro screening and in vivo animal studies for antimicrobial and anti-biofilm work, and the 3D HEE tissue model for wound care and biomaterials testing.

iFyber operates as a B2B enterprise services business, engaging clients through direct sales, website contact, and email to scope custom project work; pricing is not publicly disclosed and contracts are quoted on a per-project basis. Primary customer segments are medical device and wound care developers—often requiring FDA 510(k) submission support, biocompatibility evaluation, and antimicrobial or biofilm efficacy testing—supplemented by diagnostics companies and specialty textile manufacturers. The company has produced at least one disclosed co-development engagement, a 2021 collaboration with SweetBio, Inc. evaluating the APIS wound product via a joint publication in the International Journal of Biomaterials. No institutional venture capital is disclosed; the only recorded funding event is a $150,000 National Science Foundation grant in December 2012, suggesting the company has been bootstrapped or founder-financed for most of its operating life. Leadership team, headcount exact figure, and revenue figures are not disclosed in the public source set, indicating a small, privately held operation (headcount stated as 11–50 employees) operating primarily in North America.

iFyber firmographics

Firmographics
Name
iFyber
Legal name
iFyber, LLC
Website
https://ifyber.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
iFyber is a U.S.-based preclinical contract research organization (CRO) providing custom laboratory testing and regulatory consulting—including biofilm, antimicrobial, tissue model, LC-MS, and virology services—to medical device, wound care, diagnostic, and specialty textile developers.
Ownership category
akta.pro rank

iFyber industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Testing Laboratories and Services (541380), Other Scientific and Technical Consulting Services (541690), Medical and Diagnostic Laboratories (62151)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYAFALADAC
Regulatory Consulting & Compliance Program Management (FDA/USDA/EFSA)
Agriculture & Food Production/Food Safety, Testing & Certification/Regulatory Compliance Testing & Consulting (FDA/USDA/EFSA, HACCP)

Keywords

  • Preclinical CRO
  • Contract research
  • Medical device testing
  • Antimicrobial efficacy testing
  • Biofilm testing services

Where iFyber is headquartered

Location

Headquarters

HQ city
Ithaca
HQ country
United States
HQ region
North America

Offices1 record

Markets served

iFyber business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Research Services: Fee-for-service preclinical research contracts providing laboratory testing, method development, and regulatory consulting to medical device, wound care, diagnostics, and specialty textile companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

iFyber product offering

Product offering

Core offering

iFyber is a preclinical contract research organization (CRO) that provides fee-for-service laboratory testing, custom method development, and regulatory consulting to medical device, wound care, diagnostics, and specialty textile companies. Its services span microbial control (biofilm testing, antimicrobial efficacy, sterilization validation), cell and tissue culture (cell-based assays, ex vivo and 3D tissue models, histology and imaging), LC-MS analytical chemistry, virology testing, monoclonal antibody characterization, and chemical detection diagnostics.

Product overview

iFyber is a preclinical contract research organization (CRO) providing integrated research services for medical device, wound care, diagnostic, and specialty textile development. The company operates as a unified service platform rather than a software product, offering consulting-driven experimental design combined with laboratory execution across multiple testing disciplines. The portfolio encompasses microbial control services (biofilm testing, antimicrobial efficacy testing, sterilization validation), cell and tissue culture capabilities (cell-based assays, tissue models including ex vivo porcine dermal models and 3D Human Epidermis Equivalent, histology and imaging), LC-MS analytical services, virology testing, analytical services for monoclonal antibodies and chemical detection, and specialized expertise in medical devices, wound care devices, diagnostics, and specialty textiles. White papers documenting proprietary methodologies include ex vivo biofilm models, biofilm visualization techniques, 3D HEE models, dental device biocompatibility frameworks, antibiotic and antifungal efficacy screening, and tissue decellularization evaluation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Preclinical CRO Services Integrated preclinical contract research services encompassing study design, experimental execution, and regulatory consulting to support medical device, wound care, diagnostic, and specialty textile product development.
  • Microbial Control Services

Companies that use iFyber

Customer profile

Segments4 records

Ideal customer profiles4 records

iFyber technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

iFyber partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • SweetBio, Inc.minorStrategic or Co-development Partner · 23 March 2021Collaborative research partnership for wound care product evaluation. Joint publication titled 'Microenvironment Influence of a Novel Bioengineered Wound Product, APIS®: A Preliminary In Vitro Analysis of Inflammatory Marker and Growth Factor Secretion' published in International Journal of Biomaterials (2021). The partnership evaluated the novel APIS wound product's ability to balance wound microenvironment by reducing MMP-9/TIMP-1 ratio and triggering growth factor release from fibroblasts.

Recent moves5 records

Expansion highlights4 records

iFyber competitors and assessment

Company assessment

Direct peers

  • Nelson Laboratories: Nelson Labs is a dedicated microbiology and analytical testing CRO specializing in medical device sterilization validation, biocompatibility, and antimicrobial efficacy testing. It is a direct peer to iFyber given the highly overlapping focus on medical device and wound care product safety, efficacy, and FDA submission-support testing.
  • Toxikon Corporation: Toxikon is a preclinical CRO focused on medical device biocompatibility, toxicology, and materials characterization. It directly competes with iFyber's medical device safety and biocompatibility testing work for FDA submissions.
  • Microtest Laboratories: Microtest Laboratories is a contract testing lab focused on medical device microbiology, sterilization validation, and packaging/testing services. It is a direct peer to iFyber given the overlapping focus on medical device antimicrobial efficacy and sterilization validation workflows.
  • North American Science Associates (NAMSA): NAMSA is a medical device-focused CRO offering preclinical, biological safety, and regulatory consulting services. It directly competes with iFyber's integrated preclinical testing plus FDA 510(k) regulatory support for medical device developers.

Broad incumbents

  • Labcorp Drug Development (formerly Covance): Labcorp's development services business spans central lab, preclinical, and analytical services across pharma and medtech. It is a broad incumbent whose central lab and preclinical offerings overlap with iFyber's analytical and preclinical testing capabilities.
  • Eurofins Scientific: Eurofins is a global analytical testing incumbent with dedicated medical device, pharmaceutical, and microbiology service lines. It is comparable as a broad incumbent offering overlapping antimicrobial, biocompatibility, and analytical services—though at much greater scale and geographic breadth than iFyber.
  • WuXi AppTec: WuXi AppTec is a large global CRO/CDMO with preclinical testing, analytical chemistry, and regulatory capabilities. It is comparable as a broad incumbent offering testing services that overlap with iFyber's preclinical and analytical offerings, primarily serving medical device and biopharma clients.
  • Charles River Laboratories: Charles River is a global life sciences CRO incumbent with significant preclinical safety, microbiology, and endotoxin testing capabilities. It is comparable as a broad incumbent serving medical device and biopharma end-markets that also overlap with iFyber's preclinical testing focus.
  • BioReliance (Merck KGaA / Sigma-Aldrich): BioReliance is a biopharmaceutical testing services provider offering biosafety, analytical, and microbiology testing to medical product developers. It is comparable as a broad incumbent whose microbiology and analytical offerings overlap with iFyber's antimicrobial and LC-MS work.

Emerging players

  • Pace Analytical Life Sciences: Pace Analytical provides analytical and life sciences testing services including microbiology and chemistry for regulated industries. It is an emerging/larger-but-focused player whose analytical chemistry and microbiology capabilities partially overlap with iFyber's LC-MS and microbial control services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

iFyber social profiles

Digital presence

iFyber financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iFyber leadership team

Management profile

Number of profiles

iFyber funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iFyber M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iFyber

What does iFyber do?

iFyber is a preclinical contract research organization (CRO) that provides fee-for-service laboratory testing, custom method development, and regulatory consulting to medical device, wound care, diagnostics, and specialty textile companies. Its services span microbial control (biofilm testing, antimicrobial efficacy, sterilization validation), cell and tissue culture (cell-based assays, ex vivo and 3D tissue models, histology and imaging), LC-MS analytical chemistry, virology testing, monoclonal antibody characterization, and chemical detection diagnostics.

Is iFyber a public or private company?

iFyber is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was iFyber founded?

iFyber was founded in 2009. It employs 11 to 50 people.

Where is iFyber based?

iFyber is headquartered in Ithaca, United States, in the North America region.

How does iFyber make money?

One revenue line is on record: contract Research Services.

Who are iFyber's main competitors?

Direct peers on record are Nelson Laboratories, Toxikon Corporation, Microtest Laboratories and North American Science Associates (NAMSA). Broad incumbents are Labcorp Drug Development (formerly Covance), Eurofins Scientific, WuXi AppTec, Charles River Laboratories and BioReliance (Merck KGaA / Sigma-Aldrich). Pace Analytical Life Sciences is listed as an emerging player.

Does iFyber have an API?

No public API is recorded for iFyber.

What industry is iFyber in?

iFyber's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAC, Toxicology & Safety Assessment CROs (GLP), with a secondary code of HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs. Its NAICS code is 541380 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireMerakris Therapeutics and iFyber Collaboration Receives Top SAWC Research Award for MTX-001 Wound Healing Study in Human Skin ModelMerakris Therapeutics and iFyber received the Best Laboratory Research Award at the SAWC Spring 2026 for preclinical data showing MTX-001 accelerates wound closure in a human skin model. The study demonstrated statistically significant wound healing, re-epithelialization, and biodistribution of the biologic. Merakris is advancing MTX-001 in a Phase 2 trial for venous leg ulcers, with FDA filings planned later this year.IfyberChoosing Between Immunoassays and Molecular AssaysAn iFyber Research Scientist, Mariely Medina-Rivera, outlines how to choose between immunoassays and molecular assays during in vitro diagnostics development, covering specimen type, sensitivity and specificity, intended usage, cost and turnaround time. She notes immunoassays are faster and cheaper, while molecular assays offer higher sensitivity, with isothermal amplification methods like LAMP and RPA improving speed.FederalregisterProspective Grant of Start-Up Exclusive Evaluation Option License Agreement: Nitric Oxide (NO) Releasing Materials for Use in Medical Devices Related to Microbial Management and Wound CareThe National Institutes of Health (NIH) has announced its intent to grant iFyber LLC a Start-Up Exclusive Evaluation Option License for a family of nitric oxide-releasing diazeniumdiolated acrylonitrile-based polymers used in medical devices and wound care applications. The license, covering six patent applications and issued patents across multiple jurisdictions, would give iFyber worldwide rights in the specified field of medical tubing and wound healing devices. The NIH is accepting public comments for 15 days before finalizing the agreement, with iFyber gaining the option to convert this evaluation license into an exclusive patent license upon expiration.